Yoshinari Uehara

Prof. Yoshinari Uehara

Faculty of Sports and Health Science, Fukuoka University, Fukuoka 814-0180, Japan
orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2007 in Atherosclerosis
Verified
Journal Article
Closed access
Yoshinari UeharaYoshinari Uehara
Yoshinari Uehara
SMShin-Ichiro Miura
Shin-Ichiro Miura
AEArnold von Eckardstein
Arnold von Eckardstein
SASatomi Abe
Satomi Abe
AFAkihiro Fujii
Akihiro Fujii
KSKeijiro Saku
Keijiro Saku

1 June 2008 in Brain Research
Verified
Journal Article
Closed access
Yoshinari UeharaYoshinari Uehara
Yoshinari Uehara
TYTatsuo Yamada
Tatsuo Yamada
YBYasuhiko Baba
Yasuhiko Baba
SMShin-Ichiro Miura
Shin-Ichiro Miura
SASatomi Abe
Satomi Abe
KSKeijiro Saku
Keijiro Saku

1 April 2013 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
Yoshinari UeharaYoshinari Uehara
Yoshinari Uehara
SMShin-Ichiro Miura
Shin-Ichiro Miura
EYEiji Yahiro
Eiji Yahiro
KSKeijiro Saku
Keijiro Saku
For the past century, the renin–angiotensin system (RAS) has been recognized as one of the major blood pressure-regulating systems. Angiotensin II (Ang II) is the final physiologically active product of RAS, and it works not only as a strong vasopressor but also as a promotor of tissue remodeling in various organs such as heart, arteries, and kidneys. RAS is the predominant pathway of Ang II formation in human plasma, but not in the tissues. There are several alternative pathways producing angiotensin II in human tissues, and they are involved in structural remodeling of the cardiovascular system. Proteinases such as chymase, kallikrein, cathepsin G, and elastase- 2 are probably responsible for angiotensin-converting enzyme (ACE)-independent Ang II formation in human tissues. In particular, chymase is an important Ang II-generating enzyme in the human heart. It is important to elucidate the mechanisms of the ACEindependent Ang II formation in human tissues; long-term inhibition of the local Ang II formation may become one of the strategies to prevent cardiovascular remodeling.

20 May 2013 in Journal of the American Heart Association
Verified
Journal Article
Open access
Yoshinari UeharaYoshinari Uehara
Yoshinari Uehara
SASetsuko Ando
Setsuko Ando
EYEiji Yahiro
Eiji Yahiro
KOKosuke Oniki
Kosuke Oniki
MAMakoto Ayaori
Makoto Ayaori
KSKeijirio Saku
Keijirio Saku
Background: Apolipoprotein (apo) A‐I is a major high‐density lipoprotein ( HDL ) protein that causes cholesterol efflux from peripheral cells through the ATP ‐binding cassette transporter A1 ( ABCA 1), thus generating HDL and reversing the macrophage foam cell phenotype. Pre‐β 1 HDL is the smallest subfraction of HDL , which is believed to represent newly formed HDL , and it is the most active acceptor of free cholesterol. Furthermore it has a possible protective function against cardiovascular disease ( CVD ). We developed a novel apoA‐I mimetic peptide without phospholipids (Fukuoka University ApoA‐I Mimetic Peptide, FAMP ). Methods and Results: FAMP type 5 ( FAMP 5) had a high capacity for cholesterol efflux from A172 cells and mouse and human macrophages in vitro, and the efflux was mainly dependent on ABCA 1 transporter. Incubation of FAMP 5 with human HDL or whole plasma generated small HDL particles, and charged apoA‐I‐rich particles migrated as pre‐β HDL on agarose gel electrophoresis. Sixteen weeks of treatment with FAMP 5 significantly suppressed aortic plaque formation (scrambled FAMP , 31.3±8.9% versus high‐dose FAMP 5, 16.2±5.0%; P <0.01) and plasma C‐reactive protein and monocyte chemoattractant protein‐1 in apoE‐deficient mice fed a high‐fat diet. In addition, it significantly enhanced HDL ‐mediated cholesterol efflux capacity from the mice. Conclusions: A newly developed apoA‐I mimetic peptide, FAMP , has an antiatherosclerotic effect through the enhancement of the biological function of HDL . FAMP may have significant atheroprotective potential and prove to be a new therapeutic tool for CVD .

Verified
Journal Article
Open access
PDF file
MDManami Deshimaru
Manami Deshimaru
MKMariko Kinoshita-Kawada
Mariko Kinoshita-Kawada
KKKaori Kubota
Kaori Kubota
TWTakuya Watanabe
Takuya Watanabe
YTYasuyoshi TANAKA
Yasuyoshi TANAKA
YTYoshio Tsuboi
Yoshio Tsuboi
A common pathological hallmark of several neurodegenerative diseases, including amyotrophic lateral sclerosis, is cytoplasmic mislocalization and aggregation of nuclear RNA-binding protein TDP-43. Perry disease, which displays inherited atypical parkinsonism, is a type of TDP-43 proteinopathy. The causative gene DCTN1 encodes the largest subunit of the dynactin complex. Dynactin associates with the microtubule-based motor cytoplasmic dynein and is required for dynein-mediated long-distance retrograde transport. Perry disease-linked missense mutations (e.g., p.G71A) reside within the CAP-Gly domain and impair the microtubule-binding abilities of DCTN1. However, molecular mechanisms by which such DCTN1 mutations cause TDP-43 proteinopathy remain unclear. We found that DCTN1 bound to TDP-43. Biochemical analysis using a panel of truncated mutants revealed that the DCTN1 CAP-Gly-basic supradomain, dynactin domain, and C-terminal region interacted with TDP-43, preferentially through its C-terminal region. Remarkably, the p.G71A mutation affected the TDP-43-interacting ability of DCTN1. Overexpression of DCTN1G71A, the dynactin-domain fragment, or C-terminal fragment, but not the CAP-Gly-basic fragment, induced cytoplasmic mislocalization and aggregation of TDP-43, suggesting functional modularity among TDP-43-interacting domains of DCTN1. We thus identified DCTN1 as a new player in TDP-43 cytoplasmic-nuclear transport, and showed that dysregulation of DCTN1-TDP-43 interactions triggers mislocalization and aggregation of TDP-43, thus providing insights into the pathological mechanisms of Perry disease and other TDP-43 proteinopathies.

18 March 2019 in BioMed Research International
Verified
Journal Article
Open access
PDF file
KHKoichi Hyakutake
Koichi Hyakutake
TMTakashi Morishita
Takashi Morishita
KSKazuya Saita
Kazuya Saita
HFHiroyuki Fukuda
Hiroyuki Fukuda
ESEtsuji Shiota
Etsuji Shiota
Yoshinari UeharaYoshinari Uehara
Yoshinari Uehara
Introduction.Robotic therapy has drawn attention in the rehabilitation field including home-based rehabilitation. A previous study has reported that home-based therapy could be more effective for increasing upper limb activity than facility-based therapy. The single-joint hybrid assistive limb (HAL-SJ) is an exoskeleton robot developed according to the interactive biofeedback theory, and several studies have shown its effectiveness for upper limb function in stroke patients. A study of home-based robotic therapy has shown to enhance rehabilitation effectiveness for stroke patient with a paretic upper limb. However, home-based therapy involving a HAL-SJ in stroke patients with paretic upper limbs has not been investigated. The present study aimed to investigate paretic upper limb activity and function with home-based robotic therapy involving a HAL-SJ in stroke patients.Materials and Methods.A home-based robotic therapy program involving a HAL-SJ was performed for 30 min per session followed by standard therapy for 30 min per session, 2 times a week, for 4 weeks (i.e., completion of all 8 sessions involved 8 h of rehabilitation), at home. After the intervention, patients were followed up by telephone and home visits for 8 weeks. The paretic upper limb activity and function were assessed using the Motor Activity Log (MAL; amount of use (AOU)), arm triaxial accelerometry (laterality index (LI)), the Fugl–Meyer assessment (FMA), and the action research arm test (ARAT), at baseline and week 4 and week 12 after the start of training.Results.The study included 10 stroke patients (5 men; mean age, 61.1 ± 7.1 years). The AOU scores and LI significantly improved at week 4 after the start of training (p<0.05). However, no significant changes were observed in the LI at week 12 (p=0.161) and the FMA scores at both week 4 and week 12 (p=0.059 andp=0.083, respectively). The ARAT scores significantly improved at both week 4 and week 12 (p<0.05).Conclusion.Home-based robotic therapy combined with conventional therapy could be a valuable approach for increasing paretic upper limb activity and maintaining paretic upper limb function in the chronic phase of stroke.